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The entire landscape of cancer management in primary care, from case identification to the 
management of those living with and beyond cancer, is evolving rapidly in the face of the 
coronavirus (COVID-19) pandemic.1 In a climate of fear and mandated avoidance of all but 
essential clinical services, delays in patient, population and healthcare system responses to 
suspected cancer symptoms seem inevitable.   
 
Screening, case identification and referral 
UK national cancer screening programmes - accounting for approximately 5% of all cancer 
diagnoses each year - have been suspended.2 As a consequence, early diagnoses from 
screening will be delayed, and symptom-based diagnosis of cancer becomes more 
important.3 Postponing screening sends a message to the public and primary care that 
cancer can wait. 
 
Timely presentation with symptoms is driven by a combination of appraising symptoms as 
warranting attention, perceived or actual ability to consult a healthcare professional, 
perceived consequences of seeking help, and priority over competing goals.4 It is likely that 
patients with well recognized ‘red flag’ symptoms such as a new lump or rectal bleeding will 
continue to present to primary care. However with COVID-19 at the forefront, vague cancer 
symptoms such as fatigue, change in bowel habit and weight loss may be dismissed by the 
patient as trivial.5 Respiratory symptoms including persistent cough may be attributed to 
COVID-19 and not acted on. Patients may be reluctant to present due to fear of mixing with 
others, limited capacity to use video/teleconsultations and worry about wasting the doctor’s 
time.6,7 
 
For GPs, the COVID-19 pandemic is affecting all aspects of normal working life, including a 
reduced workforce due to illness and self-isolation, and the availability of appointments and 
investigations in primary and secondary care. The huge shift to telephone triage and video 
consultations may result in missed cues, reduced examination findings and loss of the 
clinician’s ‘gut feeling’. Remote consulting may also be less suited to more vulnerable 
patients and those from lower socioeconomic backgrounds, compounding inequalities 
already apparent in early cancer diagnosis.8 If patients with cancer symptoms do present to 
primary care, there is no consensus on how they should be managed during the pandemic, 
or safety-netted. When patients are referred, they are likely to be triaged or delayed.9 For 
example, the cancellation of all but emergency endoscopy will inevitably prolong the 
diagnosis of gastrointestinal cancers. 
 
Cancer patient management and follow up 
Many patients with cancer, especially those undergoing chemotherapy, radical radiotherapy 
and immunotherapy, are at greater risk from the symptoms and sequelae of COVID-19. NHS 
guidelines state that patients will want to discuss whether the benefits of continuing active 
cancer treatment outweigh the risks of potentially being seriously unwell if they contract 
COVID-19 - a role that could well fall to primary care.9 The UK cancer charity Macmillan 
reports that a quarter of calls to its support line are from patients with cancer, anxious 
about coronavirus.10 While cancer charities provide a vital support role, primary care needs 
to support the physical and mental health of patients for whom potentially lifesaving cancer 
treatments are being postponed.  
 
Cancer treatments remain a priority in the healthcare system, but as any system becomes 
increasingly occupied with caring for COVID-19 patients, prioritisation inevitably becomes 
the norm. Patients needing immediate care are receiving treatment, but where it is possible 
to delay treatments, then this will happen. Guidance to help these difficult decisions may 
become variable, inconsistent and hurried, with the inevitable risk to patient outcomes. In 
all of this, the psychological impact on patients and clinical staff will be enormous.  
 
Implications for primary care 
The COVID-19 pandemic crisis has highlighted potential solutions for dealing with future 
global health threats. Though we are in uncharted waters, it is likely that the use of remote 
consulting will grow. Greater flexibility in accessing healthcare may serve to advantage some 
population groups, but risks disadvantaging others. If done well, it could benefit previously 
underserved patient populations such as those living in remote areas.  
 
Behavioural interventions to encourage the timely symptomatic diagnosis of cancer are 
important. Public awareness campaigns should signal that early help-seeking is welcome 
and legitimate, and may utilise social media and community networks that have grown in 
response to COVID-19. Clinicians must be aware of ‘diagnostic overshadowing’ from COVID-
19, remember that patients may have significantly delayed presentation already, and may 
need additional support navigating next steps in terms of their referral and safety-netting. 
 
If cancer is suspected, clinicians should not be deterred from referring patients urgently 
because of COVID-19 or other future global health threats. However, they may have to 
accept triage and risk stratification of patients with potentially serious disease. Biomarker 
and machine learning approaches may support this, enabling prioritisation of patients who 
are at greatest risk and diverting healthcare resources towards managing seriously ill 
patients.  
 
When patients are diagnosed with cancer, or are living with or beyond cancer, primary care 
may have to accept enhanced roles in supporting decisions on cancer treatment, palliative 
care and advanced planning around resuscitation and preferred places of care. 
 
Lastly, once ‘normal service’ resumes at a population and health service level, there will be a 
huge backlog of patients with potential cancer symptoms needing urgent assessment. 
Planning for recovery should commence as soon as possible.  
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